News

Judge Finds Watson Infringed Elan's Naprelan Patent

IP Law 360
August 14, 2008

Media Mention

A federal judge recently found that Watson Pharmaceuticals Inc. willfully infringed the patent for Elan Corporation's anti-inflammatory drug, Naprelan. The judge ruled that Andrx Pharmaceuticals, Inc., now part of Watson, had been unable to invent its own noninfringing product that would match the benefits of Naprelan and subsequently copied Elan's patented product, making only trivial changes. Elan, a Finnegan client, will be presenting its damages case before the court on September 19, 2008.